Disclaimer: The information provided herein is my opinion only. Under any circumstances do any statement here represent a recommendation to buy or sell, nor do i make any claims or promises for profits. You are responsible for your own action.consult with your financial adviser before taking any action
Sunday, January 12, 2020
Tuesday, January 7, 2020
MCX
A candidate for long term play..........beneficial candidate for sebi's margin policy implementation. buy@1200-1215 level tgt 7000.
Thursday, January 2, 2020
Wednesday, December 11, 2019

A small cap pharma company with a market cap of 3389 cr It is a high cash reserved company.it is in a 3 year breakout
buy@402-410 levels for a tgt of 520.
mkt cap-3389, pe 13.45
sales improved during 2016-2019 is 1344 cr to 1643
net profit improved from 163 cr to 193 cr during 2016-2019
eps improved from 19.16 to 24.11 during 2016-2019.
Tuesday, November 26, 2019
AFTER A LONG PERIOD OF CONSOLIDATION MID CAP PHARMA SECTOR SEEMS A TO BE RECOVERY MODE. IAM BULLISH WITH SELECTIVE PHARMA STOCKS WITH MEDIUM TERM/LONG TERM PROSPECTIVE.
1. MY PRIME PICK IS ASTRAZEN PHARMA BUY@2500-2525 LEVEL TGT 4400-4500
2.DIVISLAB BUY@1650-1675 LEVEL TGT 2000-2100
3. IPCA LAB BUY@950-1050 LEVEL TGT 1500-1600
4 .JBCHEMPHARMA BUY@380-385 LEVEL TGT 550-575
Subscribe to:
Posts (Atom)




